• SARS-CoV-2 Nucleocapsid Disrupts GADD34-Mediated Immunity

  2026-05-27

  This study reveals that the SARS-CoV-2 nucleocapsid protein impairs host innate immunity by sequestering GADD34 mRNA into atypical stress granule-like foci, thereby suppressing interferon responses. These mechanistic insights deepen our understanding of viral immune evasion and suggest new directions for probing antiviral defense pathways.

• Applied Use of Trypsin: Serine Protease Workflows & Innovati

  2026-05-27

  Trypsin, a serine protease, powers precise protein digestion and advanced cell culture workflows—unlocking new frontiers in wound healing, neurogenic inflammation, and viral membrane fusion studies. This guide details protocol optimizations, troubleshooting, and translational insights to help researchers leverage APExBIO’s Trypsin (BA5744) for robust, reproducible results.

• Cefiderocol vs. β-lactamase Inhibitors: Resistance in Europe

  2026-05-26

  This study systematically compares the in vitro activity of cefiderocol with that of both approved and experimental β-lactam/β-lactamase inhibitor combinations against a large set of European Enterobacterales isolates, including those resistant to meropenem. The findings reveal cefiderocol's superior or comparable efficacy, offering new insights for the management of multidrug-resistant infections.

• Cy3 Rabbit Anti-Goat IgG (H+L) Antibody: Workflow Guidance

  2026-05-26

  The Cy3 Rabbit Anti-Goat IgG (H+L) Antibody addresses the need for highly specific, fluorescence-based detection of goat IgG in immunocytochemistry, immunohistochemistry, flow cytometry, and ELISA. It should be used exclusively with goat primary antibodies in validated immunodetection workflows; it is not suitable for direct detection of non-goat species or applications outside these modalities.

• E-64: Applied Workflows for Precise Cysteine Protease Inhibi

  2026-05-25

  E-64, a potent L-trans-epoxysuccinyl peptide, delivers irreversible cysteine protease inhibition for advanced cell biology and cancer research. This guide translates the latest mechanistic findings and protocol innovations into actionable workflows and troubleshooting strategies for maximizing assay reliability and scientific impact.

• NLRP10 Regulates Keratinocyte Survival and Barrier Function

  2026-05-25

  This study demonstrates that NLRP10 is essential for maintaining epidermal homeostasis by promoting keratinocyte survival and p63-dependent differentiation, with direct implications for atopic dermatitis pathogenesis. By elucidating NLRP10's mechanistic roles and its regulatory impact on skin barrier integrity, the research identifies NLRP10 as a promising target for precision therapeutic strategies in chronic skin inflammation.

• Sumatriptan Succinate: 5-HT1 Receptor Agonist in Advanced Re

  2026-05-24

  Sumatriptan Succinate stands out as a precision 5-HT1 receptor agonist for migraine and neuroinflammation research, offering unrivaled receptor selectivity and well-characterized metabolic handling. This guide delivers actionable protocols, troubleshooting strategies, and comparative context to help researchers leverage APExBIO’s high-purity standard for robust modeling of serotonergic signaling and inflammatory pathways.

• HR-LCMS/MS Identifies Glabrol as an Autophagy Inducer in Ast

  2026-05-23

  This study introduces a streamlined HR-LCMS/MS-based workflow for rapid identification of autophagy-inducing phytochemicals in plant extracts, using SH-SY5Y neuroblastoma cells as a functional screen. A key finding is the discovery of Astragalus dasyanthus as a novel producer of glabrol, offering new directions for natural product-driven autophagy and metabolic regulation research.

• E-64: Precision Cysteine Protease Inhibition in Cancer Resea

  2026-05-22

  E-64, a potent L-trans-epoxysuccinyl peptide, enables precise cysteine protease inhibition for mechanistic and translational studies. Its irreversible action and quantitative potency offer workflow advantages in cancer immunology and cell biology, especially where cathepsin S activity shapes antigen presentation and tumor-immune interactions.

• Bortezomib (PS-341): Proteasome Inhibition and NSCLC Metasta

  2026-05-22

  Explore how Bortezomib (PS-341) advances research into proteasome-regulated cellular processes and apoptosis. This article uniquely connects proteasome inhibition with the latest findings in non-small cell lung cancer metastasis control, offering new direction for assay design and therapeutic exploration.

• BFH772 (VEGFR2 Inhibitor): Practical Guidance for Angiogenes

  2026-05-21

  BFH772 is a highly selective VEGFR2 inhibitor designed for precise modulation of VEGFR2-driven angiogenesis, particularly in tumor model research. It is not suitable for workflows requiring water-soluble compounds or broad-spectrum kinase inhibition due to its defined solubility and selectivity characteristics.

• Sumatriptan Succinate: Mechanisms and Translational Innovati

  2026-05-21

  Explore the unique anti-inflammatory and neurovascular mechanisms of Sumatriptan Succinate as a 5-HT1 receptor agonist. This in-depth article applies clinical insights to preclinical assay design, offering advanced guidance for serotonergic signaling research.

• Targeting SIA-cIgG/PTPN13 to Overcome Cisplatin Resistance i

  2026-05-20

  This study reveals that inhibition of sialylated cancer IgG (SIA-cIgG) enhances the efficacy of chemotherapeutic agents, including cisplatin, in head and neck squamous cell carcinoma (HNSCC) by modulating tumor stemness through the PTPN13 axis. The findings provide a mechanistic rationale for targeting SIA-cIgG to overcome chemoresistance and improve outcomes in HNSCC.

• Oxaliplatin in Cancer Biology: Mechanisms, Synergy, and Assa

  2026-05-20

  Explore the scientific underpinnings and translational value of Oxaliplatin, a platinum-based chemotherapeutic agent, with a deep focus on its mechanism of action, synergy with targeted therapies, and experimental design for cancer research. This article uniquely examines how PAK1-targeted strategies redefine Oxaliplatin's role in metastatic colorectal cancer therapy.

• GSTA1 Drives Glutathione Depletion in α-Amanitin Hepatotoxic

  2026-05-19

  This study reveals that GSTA1, typically an antioxidant enzyme, paradoxically intensifies α-amanitin-induced liver injury by driving glutathione depletion and oxidative stress. The findings reposition GSTA1 as both a direct therapeutic target and a biomarker for acute amatoxin hepatotoxicity, informing future experimental strategies targeting redox pathways.

473 records 4/32 page Previous Next 12345 下5页 Last page